CN107184953A - 一种抗菌脂肽皮脂膜修复组合物及其应用 - Google Patents
一种抗菌脂肽皮脂膜修复组合物及其应用 Download PDFInfo
- Publication number
- CN107184953A CN107184953A CN201710368562.5A CN201710368562A CN107184953A CN 107184953 A CN107184953 A CN 107184953A CN 201710368562 A CN201710368562 A CN 201710368562A CN 107184953 A CN107184953 A CN 107184953A
- Authority
- CN
- China
- Prior art keywords
- sebum film
- remediation composition
- antibacterial
- parts
- bacillus subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002374 sebum Anatomy 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000005067 remediation Methods 0.000 title claims abstract description 40
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 34
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 46
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 46
- 229920001661 Chitosan Polymers 0.000 claims abstract description 42
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 42
- 230000003115 biocidal effect Effects 0.000 claims abstract description 31
- 238000000855 fermentation Methods 0.000 claims abstract description 25
- 230000004151 fermentation Effects 0.000 claims abstract description 25
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 21
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 21
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 17
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000010410 layer Substances 0.000 claims description 21
- 239000000306 component Substances 0.000 claims description 12
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 239000004519 grease Substances 0.000 claims description 9
- 239000011241 protective layer Substances 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000001888 Peptone Substances 0.000 claims description 6
- 108010080698 Peptones Proteins 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 229940041514 candida albicans extract Drugs 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000012533 medium component Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 235000019319 peptone Nutrition 0.000 claims description 6
- 239000012138 yeast extract Substances 0.000 claims description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000028990 Skin injury Diseases 0.000 abstract description 2
- 230000001857 anti-mycotic effect Effects 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 239000002543 antimycotic Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010012504 Dermatophytosis Diseases 0.000 description 2
- 241001460074 Microsporum distortum Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- SNGZVXPRGLTKNU-RGMNGODLSA-N [Na].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Na].C(CC)N[C@@H](CCO)C(=O)O SNGZVXPRGLTKNU-RGMNGODLSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- -1 phosphorus Lipid Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000028706 ribosome biogenesis Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000005368 silicate glass Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00604—Multilayer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种抗菌脂肽皮脂膜修复组合物及其应用。所述皮脂膜修复组合物,药效成分如下:羧甲基壳聚糖、几丁糖、聚丙烯酸钠、抗菌肽、脂肽类抗生素;本发明还涉及该抗菌脂肽皮脂膜修复组合物的应用。本发明首次将羧甲基壳聚糖、几丁糖与枯草芽孢杆菌发酵液中提取的抗菌肽和脂肽类抗生素以及聚丙烯酸钠混合制得皮脂膜修复组合物,通过实验发现,抗菌肽和脂肽类抗生素除具有抗病毒、抗真菌和抗细菌等广谱抗菌活性和不易产生抗药性的原有优点外,还可以促进羧甲基壳聚糖与几丁糖在皮肤损伤修复过程中的效果。
Description
技术领域
本发明涉及一种抗菌脂肽皮脂膜修复组合物及其应用,属于生物医药技术领域。
背景技术
枯草芽孢杆菌(Bacillus Subtilis)由Cohn于1872年正式命名,现属于芽孢杆菌科。枯草芽孢杆菌是一类嗜热、好氧、内生抗逆孢子的革兰式阳性杆菌,容易分离培养,且能产生多种抗菌素和酶。研究表明该菌的抗菌物质能产生40多种具有不同结构和功能的抗菌物质。因其具有发达的分泌系统,近年来,科学家从枯草芽孢杆菌中分离纯化出多种有效的抗菌物质,根据产生抗菌物质的途径可分为核糖体和非核糖体合成两种。核糖体合成途径主要包括酶类、细菌素以及活性蛋白质类。非核糖体合成途径主要包括脂肽类、多肽类、磷脂类、多烯类等。其中脂肽类和肽类有很高的应用价值。目前,相关研究表明枯草芽孢杆菌所产生的抗菌物质对植物病原菌、食品腐败菌、致病菌都有抑制作用,其通过分解细菌和真菌的细胞膜或细胞壁,来造成细胞中原生质的泄露,导致菌丝断裂或畸形,同时其对孢子的萌发也有抑制作用。由于枯草芽孢杆菌产生的抗菌素是天然合成、无污染,具有广谱抗菌活性,不易产生耐药性,是目前解决抗生素和农药滥用导致耐药菌株出现和药物残留等问题的理想替代品之一。
枯草芽孢杆菌产生的抗菌物质种类丰富,其中肽类和脂肽类物质被认为是具有潜力的抗菌类药物。抗菌肽含有10~50个氨基酸,带有2~9个正电荷,具有高稳定性,对酸、碱、高温等环境条件有着很高的耐性,且抗菌活性高、抗菌谱广、无毒副作用、无残留和无污染等优点。脂肽类抗生素由Arima等人于1968年在枯草芽孢杆菌中发现,商品名为表面活性素(Surfaction)。其表现出两亲性特征,含有亲水性氨基酸,在中性pH下分子带负电荷,具有良好的水溶性;含有脂肪酸链和疏水性基团,具有良好的脂溶性,易与细菌磷脂层相互反应,有很好的抗菌效果。
皮肤作为人体最大的器官,为保护人体不受外界环境侵害的重要保护屏障。而当皮肤因各种原因缺损时,往往会导致皮肤感染、体液流失,所以在早期采取有效的措施来封闭创面可避免这些症状的产生。制作一种皮脂膜修复贴,在皮肤受损伤时可以暂时替代皮肤的部分功能,保护伤口、减少感染。其主要成分包括羧甲基壳聚糖、几丁糖、抗菌肽和脂肽类抗生素。郑立等人提出羧甲基壳聚糖具有良好的吸收、保湿、止血、促进愈合等作用,且有优良的成膜性,被广泛应用于药物缓释载体(羧甲基壳聚糖膜对皮肤成纤维细胞相容性研究;郑立,陈西广等;生物化学与生物物理进展;2003,30(2):314-320)。朱其聪等人提出,几丁糖可促进上皮细胞、内皮细胞生长而抑制成纤维细胞生长的医用高分子多糖物质,临床上应用于烧伤、褥疮、外伤、溃疡、脓肿等治疗均有良好效果(几丁糖、透明质酸酶治疗多烯紫杉醇外渗性大鼠皮肤损伤;朱其聪,李爱民等;癌症;2007,26(4):346-350)。
中国专利文献CN101892177A(申请号201010129850.3)公开了一种微生物发酵生产抗真菌脂肽和其抗真菌脂肽的皮肤擦剂,属于生物技术领域。具体涉及一种发酵糖质原料生产抗真菌脂肽的微生物枯草芽孢杆菌BI1(Bacillus subtilis BI1),保藏号为CGMCCNo.3412,同时本发明还涉及利用该微生物发酵生产的抗真菌脂肽提取物和含该提取物的涂膜剂及其涂膜剂的制备方法。采用本发明的涂膜剂治疗皮肤癣病,平均治愈时间7天,治愈率达到100%,为患者治疗皮肤癣病提供了一种良好的治疗药物。
中国专利文献CN205181606U(申请号CN201520835574.0)公开了一种创面修复贴。该创面修复贴采用生物玻璃作为主要材料,可吸附和稳定创面组织,有抑菌、促进愈合的功效。但生物玻璃是一种硅酸盐玻璃,属于人工生物材料。
发明内容
本发明针对现有技术的不足,提供一种抗菌脂肽皮脂膜修复组合物及其应用。
本发明技术方案如下:
一种皮脂膜修复组合物,药效成分如下,均为重量份:
羧甲基壳聚糖2~5份,几丁糖0.5~2份,聚丙烯酸钠1~2份,抗菌肽2~3份,脂肽类抗生素2~3份;
所述抗菌肽、抗脂肽类抗生素为将枯草芽孢杆菌发酵液经分离步骤后,通过提取抗菌肽、抗脂肽类抗生素获得;
所述为将枯草芽孢杆菌发酵液经分离步骤后,通过提取抗脂肽类抗生素步骤获得。
根据本发明优选的,药效成分如下,均为重量份:
羧甲基壳聚糖5份,几丁糖2份,聚丙烯酸钠1.5份,抗菌肽3份,脂肽类抗生素3份。
根据本发明优选的,所述枯草芽孢杆菌发酵液采用如下方法制备:
(1)将枯草芽孢杆菌接种于液体培养基中进行活化培养至对数生长期,制得活化菌体;
所述液体培养基组分如下,均为重量百分比:
酵母膏0.5~1%,蛋白胨0.7~1%,氯化钠0.5~1.2%,余量水,pH7.0~7.2;
(2)将步骤(1)制得的活化菌体按体积百分比3~5%接种于液体发酵培养基中,在28~38℃下,发酵培养24~48小时,制得微生物发酵液;
所述液体发酵培养基组分如下,均为重量百分比:
酵母膏0.1~0.3%,蛋白胨0.7~1%,葡萄糖1~1.5%,L-谷氨酸0.1~0.5%,谷氨酸钠0.1~0.5%,L-苯丙氨酸0.1~0.5%,淀粉0.05~0.1%,糊精0.05~0.1%,磷酸二氢钾0.07~0.1%,硫酸镁0.01~0.05%,氯化钾0.01~0.05%,余量水,pH7.0~7.2。
根据本发明优选的,所述分离步骤如下:
(i)将微生物发酵液在4℃、8000r/min的条件下离心15~20min,取上清,调pH至2.0~2.5,4℃沉淀1h,然后10000r/min的条件下离心15~20min,取沉淀,用体积百分比浓度为70%的甲醇溶液溶解提取2~4次,调pH值至中性,经旋转蒸发仪除去甲醇后真空干燥,制得抗菌粗提物;
(ii)将步骤(i)制取的抗菌粗提物经甲醇溶解,0.45μM微孔滤膜过滤,上样于Sephadex LH-20柱,分段收集样品,通过TLC检测,获得含抗菌肽和脂肽类抗生素的馏分。
根据本发明进一步优选的,所述步骤(i)中,pH调节剂为5.5~6.5mol/L的HCl。
根据本发明进一步优选的,所述步骤(i)中,真空干燥条件为40℃真空干燥55~65min。
根据本发明进一步优选的,所述步骤(i)中,所述甲醇溶液溶解提取时间为2小时,提取过程中磁力搅拌,提取后过滤去除沉淀。
根据本发明进一步优选的,所述步骤(ii)中,所述含抗菌肽和脂肽类抗生素的馏分用HPLC进行进一步纯化。
根据本发明优选的,所述枯草芽孢杆菌为购自中国普通微生物菌种保藏管理中心(CGMCC),保藏编号为1.1413的枯草芽孢杆菌。
一种枯草芽孢杆菌抗菌脂肽皮脂膜修复贴,包括透气层、压敏胶层和保护层,压敏胶层设置于透气层与保护层之间,上述皮脂膜修复组合物涂覆于压敏胶层的外表面。
上述枯草芽孢杆菌抗菌脂肽皮脂膜修复贴的制备方法,步骤如下:
a、按重量份比例将羧甲基壳聚糖、几丁糖和聚丙烯酸钠混合均匀,然后加入抗菌肽和脂肽类抗生素,加入生理盐水溶液按重量份补足100份,制得皮脂膜修复组合物溶液;
b、将步骤a制得的皮脂膜修复组合物溶液涂敷于压敏胶层外表面,然后封装透气层和保护层,制得枯草芽孢杆菌抗菌脂肽皮脂膜修复贴。
有益效果
1、本发明首次将羧甲基壳聚糖、几丁糖与枯草芽孢杆菌发酵液中提取的抗菌肽和脂肽类抗生素以及聚丙烯酸钠混合制得皮脂膜修复组合物,通过实验发现,抗菌肽和脂肽类抗生素除具有抗病毒、抗真菌和抗细菌等广谱抗菌活性和不易产生抗药性的原有优点外,还可以促进羧甲基壳聚糖与几丁糖在皮肤损伤修复过程中的效果;
2、本发明所述的皮脂膜修复组合物中,枯草芽孢菌产生的脂类物质与皮肤表面的脂类物质非常相似,可与创面的水份通过乳化作用产生脂类膜,对创面进行保护;另外,羧甲基壳聚糖和几丁质有很好的修复功效,具有保湿、止血、促进愈合的作用。当使用皮脂膜修复贴时,会在伤口处成膜,保护皮肤不受外界微生物的侵入,可以更好的对受损皮肤组织进行修复;
3、本发明所述的皮脂膜修复组合物中,聚丙烯酸钠做为增稠剂,对人体无害,主要起乳化分散的作用,可以促进皮脂膜修复组合物成分的均匀,提高使用效果;
4、本发明所述皮脂膜修复组合物原料非人工合成材料,其来源纯天然、无污染,对人体安全、无害,所述枯草芽孢杆菌抗菌脂肽皮脂膜修复贴制作简单,成本低,临床上对烧伤、褥疮、外伤、溃疡、脓肿等治疗均有良好效果,可在临床上广泛应用。
附图说明
图1为本发明所述的一种枯草芽孢杆菌抗菌脂肽皮脂膜修复贴及其生产方法,的结构示意图;
图中:1、压敏胶层,2、保护层,3、透气层。
具体实施方式
下面结合实施例对本发明的技术方案做进一步阐述,但本发明所保护范围不限于此。
实例中涉及的仪器设备:
Amicon Ultra-15超滤管,上海俊晟生物科技有限公司;SephadexG-50凝胶柱,反相HPLC;制备型HPLC系统,Waters公司;Kromasil C18色谱柱,250×21.2mm;FD5-4真空冷冻干燥机,美国SIM公司;RE-3000B旋转蒸发仪,上海普渡生化科技有限公司。
实施例中所述枯草芽孢杆菌所述枯草芽孢杆菌为购自中国普通微生物菌种保藏管理中心(CGMCC),保藏编号为1.1413的枯草芽孢杆菌。
实施例1
一种皮脂膜修复组合物,药效成分如下,均为重量份:
羧甲基壳聚糖2份,几丁糖0.5份,聚丙烯酸钠1份,抗菌肽2.5份,脂肽类抗生素2.5份;
所述抗菌肽、抗脂肽类抗生素为将枯草芽孢杆菌发酵液经分离步骤后,通过提取抗菌肽、抗脂肽类抗生素获得;
枯草芽孢杆菌发酵液采用如下方法制备:
(1)将枯草芽孢杆菌接种于液体培养基中进行活化培养至对数生长期制得活化菌体;
液体培养基组分如下,均为重量百分比:
酵母膏0.5%,蛋白胨0.7%,氯化钠0.5%,余量水,pH 7.0;
(2)将步骤(1)制得的活化菌体按体积百分比5%接种于液体发酵培养基中,在37℃下,发酵培养30小时,制得微生物发酵液;
液体发酵培养基组分如下,均为重量百分比:
蛋白胨0.7%,酵母膏0.1%,葡萄糖1%,L-谷氨酸0.1%,谷氨酸钠0.1%,L-苯丙氨酸0.1%,淀粉0.05%,糊精0.05%,磷酸二氢钾0.07%,硫酸镁0.01%,氯化钾0.01%,余量水,pH7.0。
根据本发明优选的,所述分离步骤如下:
(i)将微生物发酵液在4℃、8000r/min的条件下离心20min,取上清,6.0mol/L的HCl调pH至2.5,4℃沉淀1h,然后10000r/min的条件下离心20min,取沉淀,用体积百分比浓度为70%的甲醇溶液溶解提取3次,调pH值至中性,经旋转蒸发仪除去甲醇后-20℃真空干燥60min,制得抗菌粗提物;
所述甲醇溶液溶解提取时间为2小时,提取过程中磁力搅拌,提取后过滤去除沉淀;
(ii)将步骤(i)制取的抗菌粗提物经甲醇溶解,0.45μM微孔滤膜过滤,上样于Sephadex LH-20柱,分段收集样品,通过TLC检测,获得含抗菌肽和脂肽类抗生素的馏分;所述含抗菌肽和脂肽类抗生素的馏分利用HPLC进行进一步纯化,制得抗菌肽、抗脂肽类抗生素。
实施例2
如实施例1所述的皮脂膜修复组合物,不同之处在于药效成分如下,均为重量份:
羧甲基壳聚糖3.5份,几丁糖1.5份,聚丙烯酸钠2份,抗菌肽2份,脂肽类抗生素2份。
实施例3
如实施例1所述的皮脂膜修复组合物,不同之处在于药效成分如下,均为重量份:
羧甲基壳聚糖5份,几丁糖2份,聚丙烯酸钠1.5份,抗菌肽3份,脂肽类抗生素3份。
实施例4
如实施例1所述的皮脂膜修复组合物,不同之处在于枯草芽孢杆购自中国普通微生物菌种保藏管理中心(CGMCC),保藏编号为1.1216的枯草芽孢杆菌。
对比例1
如实施例1所述的皮脂膜修复组合物,不同之处在于药效成分如下,均为重量份:
羧甲基壳聚糖2份,几丁糖0.5份,聚丙烯酸钠1份,甲壳素2.5份,雄黄2.5份。
对比例2
如实施例1所述的皮脂膜修复组合物,不同之处在于药效成分如下,均为重量份:
聚乙烯醇2份,透明质酸0.5份,聚丙烯酸钠1份,抗菌肽2.5份,脂肽类抗生素2.5份。
实施例5
一种枯草芽孢杆菌抗菌脂肽皮脂膜修复贴,包括透气层、压敏胶层和保护层,压敏胶层设置于透气层与保护层之间,皮脂膜修复组合物涂覆于压敏胶层的外表面;
所述枯草芽孢杆菌抗菌脂肽皮脂膜修复贴的制备方法,步骤如下:
a、按重量份比例将羧甲基壳聚糖、几丁糖和聚丙烯酸钠混合均匀,然后加入抗菌肽和脂肽类抗生素,加入生理盐水溶液按重量份补足100份,制得皮脂膜修复组合物溶液;
b、将步骤a制得的皮脂膜修复组合物溶液涂敷于压敏胶层外表面,然后封装透气层和保护层,制得枯草芽孢杆菌抗菌脂肽皮脂膜修复贴。
实验例
分别将实施例1~4及对比例1~2制得的皮脂膜修复组合物按照实施例5制备成皮脂膜修复贴,分别标号样品1~4及对照1~2,按照如下方法进行检测:
准备重量(200±10)g SPF级大鼠30只,雌雄各半。将大鼠随即分为6组,每组5只。用电动剪刀去除30只大鼠后肢的毛发,暴露皮肤直径至少5cm,观察24小时,剪毛部位未产生炎症反应。称大鼠重量,随后进行麻醉,常规消毒,制作大鼠皮肤溃疡模型(参考《不同品种大黄油糊外用抗炎作用及对大鼠皮肤溃疡、痔疮模型的影响》;白明,刘丹丹等;中国现代应用药学;2013,30(6):575-581),在其暴露皮肤切割一个圆形溃疡(1.8cm×2.5cm),将制作的皮脂膜修复贴覆盖在其创伤处,每组大鼠放置在同一笼里饲养,自由进食进水,每2h观察伤口变化,每24h更换新的修复贴,至伤口修复(溃疡面积<0.2cm×0.3cm)完全再次称大鼠重量,结果如表1所示:
表1
根据本发明实验结果,实施例1~3通过改变一种皮脂膜修复贴的药效成分比例,均能对创伤部位进行修复,疗效显著,且创口处未见流脓、发红、肿胀等感染情况。
根据本发明实验结果,实施例4通过改变提取抗菌物质的枯草芽孢杆菌型号,证实只要能产抗菌物质的枯草芽孢杆菌均能应用于本发明,但修复时间和效果较实施例1~3稍差。
根据本发明实验结果,对比例1通过替换皮脂膜修复组合物中抗菌成分,虽然对创口也有一定的治疗效果,但创口处附近出现轻微发红的感染现象,证实其没有抗菌肽、脂肽类抗生素抑菌效果好。
根据本发明实验结果,对比例2通过将皮脂膜修复组合物中的羧甲基壳聚糖和几丁质替换为功能类似的聚乙烯醇和透明质酸后,治疗时间长,效果较差,创口处出现流脓和发红的感染现象,从而证明本发明所述的技术效果是羧甲基壳聚糖和几丁质与其他成分互相作用的结果,简单采用类似功能的替代物替换后,无法获得类似的技术效果。
根据本发明实验结果可以看出,羧甲基壳聚糖、几丁糖、聚丙烯酸钠、抗菌肽和脂肽类抗生素共同作用时,脂肽类抗生素可在皮肤表面快速形成脂膜,有效防止感染,起到快速愈合创伤的技术效果。
Claims (10)
1.一种皮脂膜修复组合物,其特征在于,药效成分如下,均为重量份:
羧甲基壳聚糖2~5份,几丁糖0.5~2份,聚丙烯酸钠1~2份,抗菌肽2~3份,脂肽类抗生素2~3份;
所述抗菌肽、抗脂肽类抗生素为将枯草芽孢杆菌发酵液经分离步骤后,通过提取抗菌肽、抗脂肽类抗生素获得;
所述为将枯草芽孢杆菌发酵液经分离步骤后,通过提取抗脂肽类抗生素步骤获得。
2.如权利要求1所述的皮脂膜修复组合物,其特征在于,药效成分如下,均为重量份:
羧甲基壳聚糖5份,几丁糖2份,聚丙烯酸钠1.5份,抗菌肽3份,脂肽类抗生素3份。
3.如权利1所述的皮脂膜修复组合物,其特征在于,所述枯草芽孢杆菌发酵液采用如下方法制备:
(1)将枯草芽孢杆菌接种于液体培养基中进行活化培养至对数生长期,制得活化菌体;
所述液体培养基组分如下,均为重量百分比:
酵母膏0.5~1%,蛋白胨0.7~1%,氯化钠0.5~1.2%,余量水,pH7.0~7.2;
(2)将步骤(1)制得的活化菌体按体积百分比3~5%接种于液体发酵培养基中,在28~38℃下,发酵培养24~48小时,制得微生物发酵液;
所述液体发酵培养基组分如下,均为重量百分比:
酵母膏0.1~0.3%,蛋白胨0.7~1%,葡萄糖1~1.5%,L-谷氨酸0.1~0.5%,谷氨酸钠0.1~0.5%,L-苯丙氨酸0.1~0.5%,淀粉0.05~0.1%,糊精0.05~0.1%,磷酸二氢钾0.07~0.1%,硫酸镁0.01~0.05%,氯化钾0.01~0.05%,余量水,pH7.0~7.2。
4.如权利要求3所述的皮脂膜修复组合物,其特征在于,所述分离步骤如下:
(i)将微生物发酵液在4℃、8000r/min的条件下离心15~20min,取上清,调pH至2.0~2.5,4℃沉淀1h,然后10000r/min的条件下离心15~20min,取沉淀,用体积百分比浓度为70%的甲醇溶液溶解提取2~4次,调pH值至中性,经旋转蒸发仪除去甲醇后真空干燥,制得抗菌粗提物;
(ii)将步骤(i)制取的抗菌粗提物经甲醇溶解,0.45μM微孔滤膜过滤,上样于SephadexLH-20柱,分段收集样品,通过TLC检测,获得含抗菌肽和脂肽类抗生素的馏分。
5.如权利要求4所述的皮脂膜修复组合物,其特征在于,所述步骤(i)中,pH调节剂为5.5~6.5mol/L的HCl。
6.如权利要求4所述的皮脂膜修复组合物,其特征在于,所述步骤(i)中,真空干燥条件为40℃真空干燥55~65min;
进一步优选的,所述步骤(i)中,所述甲醇溶液溶解提取时间为2小时,提取过程中磁力搅拌,提取后过滤去除沉淀。
7.如权利要求4所述的皮脂膜修复组合物,其特征在于,所述步骤(ii)中,含抗菌肽和脂肽类抗生素的馏分利用HPLC进行进一步纯化。
8.如权利要求1所述的皮脂膜修复组合物,其特征在于,所述枯草芽孢杆菌为购自中国普通微生物菌种保藏管理中心(CGMCC),保藏编号为1.1413的枯草芽孢杆菌。
9.一种枯草芽孢杆菌抗菌脂肽皮脂膜修复贴,其特征在于,包括透气层、压敏胶层和保护层,压敏胶层设置于透气层与保护层之间,权利要求1所述皮脂膜修复组合物涂覆于压敏胶层的外表面。
10.权利要求9所述枯草芽孢杆菌抗菌脂肽皮脂膜修复贴的制备方法,其特征在于,步骤如下:
a、按重量份比例将羧甲基壳聚糖、几丁糖和聚丙烯酸钠混合均匀,然后加入抗菌肽和脂肽类抗生素,加入生理盐水溶液按重量份补足100份,制得皮脂膜修复组合物溶液;
b、将步骤a制得的皮脂膜修复组合物溶液涂敷于压敏胶层外表面,然后封装透气层和保护层,制得枯草芽孢杆菌抗菌脂肽皮脂膜修复贴。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710368562.5A CN107184953A (zh) | 2017-05-22 | 2017-05-22 | 一种抗菌脂肽皮脂膜修复组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710368562.5A CN107184953A (zh) | 2017-05-22 | 2017-05-22 | 一种抗菌脂肽皮脂膜修复组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107184953A true CN107184953A (zh) | 2017-09-22 |
Family
ID=59875319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710368562.5A Pending CN107184953A (zh) | 2017-05-22 | 2017-05-22 | 一种抗菌脂肽皮脂膜修复组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107184953A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557790A (zh) * | 2020-05-16 | 2020-08-21 | 江苏德鲁克生物科技有限公司 | 一种抗菌消毒纳米纤维医用敷料 |
CN116650380A (zh) * | 2023-06-21 | 2023-08-29 | 广州中妆美业化妆品有限公司 | 一种改善皮肤微循环的抗衰老茶叶发酵产品及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010103119A1 (en) * | 2009-03-13 | 2010-09-16 | Da Volterra | Compositions and methods for elimination of gram-negative bacteria |
CN101892177A (zh) * | 2010-03-23 | 2010-11-24 | 天津科技大学 | 一种含有抗真菌脂肽的皮肤擦剂及其制备方法 |
CN101974586A (zh) * | 2010-08-18 | 2011-02-16 | 南京农业大学 | 一种枯草芽孢杆菌抗菌脂肽的生产方法及其在饲料中的应用 |
CN102559816A (zh) * | 2011-10-13 | 2012-07-11 | 韩健宝 | 一种抗菌脂肽的制备方法及其在兽医药中的应用 |
CN104586899A (zh) * | 2015-02-09 | 2015-05-06 | 广东海洋大学 | 一种治疗褥疮的气雾剂及其制备方法 |
CN205181606U (zh) * | 2015-10-26 | 2016-04-27 | 上海硅健生物材料有限公司 | 一种创面修复贴 |
-
2017
- 2017-05-22 CN CN201710368562.5A patent/CN107184953A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010103119A1 (en) * | 2009-03-13 | 2010-09-16 | Da Volterra | Compositions and methods for elimination of gram-negative bacteria |
CN101892177A (zh) * | 2010-03-23 | 2010-11-24 | 天津科技大学 | 一种含有抗真菌脂肽的皮肤擦剂及其制备方法 |
CN101974586A (zh) * | 2010-08-18 | 2011-02-16 | 南京农业大学 | 一种枯草芽孢杆菌抗菌脂肽的生产方法及其在饲料中的应用 |
CN102559816A (zh) * | 2011-10-13 | 2012-07-11 | 韩健宝 | 一种抗菌脂肽的制备方法及其在兽医药中的应用 |
CN104586899A (zh) * | 2015-02-09 | 2015-05-06 | 广东海洋大学 | 一种治疗褥疮的气雾剂及其制备方法 |
CN205181606U (zh) * | 2015-10-26 | 2016-04-27 | 上海硅健生物材料有限公司 | 一种创面修复贴 |
Non-Patent Citations (5)
Title |
---|
吕福林等: "《小儿外科》", 30 November 2000, 人民卫生出版社 * |
姚静: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社 * |
徐怀德等: "《食品杀菌新技术》", 31 July 2005, 科学技术文献出版社 * |
程凤等: ""壳聚糖基抗菌型创伤敷料的研究进展"", 《高分子通报》 * |
赵朋超: ""枯草芽孢杆菌抗菌肽生物合成的研究进展"", 《中国生物工程杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557790A (zh) * | 2020-05-16 | 2020-08-21 | 江苏德鲁克生物科技有限公司 | 一种抗菌消毒纳米纤维医用敷料 |
CN116650380A (zh) * | 2023-06-21 | 2023-08-29 | 广州中妆美业化妆品有限公司 | 一种改善皮肤微循环的抗衰老茶叶发酵产品及其制备方法和应用 |
CN116650380B (zh) * | 2023-06-21 | 2024-05-17 | 广州中妆美业化妆品有限公司 | 一种改善皮肤微循环的抗衰老茶叶发酵产品及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duvnjak et al. | Advances in batch culture fermented Coriolus versicolor medicinal mushroom for the production of antibacterial compounds | |
WO2019000850A1 (zh) | 一种铁皮石斛内生真菌菌株及其产生的胞外多糖以及该胞外多糖的提取方法与应用 | |
CN102242165A (zh) | 一种发酵生产高分子量透明质酸钠的方法及其所用的培养基 | |
CN103555607B (zh) | 一种合欢叶片中的内生菌h6菌株分离方法及其应用 | |
CN107137628A (zh) | 来源于共生发酵生成物的透明质酸酶抑制剂及其应用 | |
CN107184953A (zh) | 一种抗菌脂肽皮脂膜修复组合物及其应用 | |
CN101531968B (zh) | 红曲协同发酵提高蛹虫草子实体和虫草菌素产量的方法 | |
US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
CN109956991B (zh) | 一种新化合物及其在制备细菌抑制剂中的应用 | |
CN108486002B (zh) | 一株产胞外多糖的罗汉果内生菌菌株及其生产胞外多糖的方法和胞外多糖的应用 | |
KR100710275B1 (ko) | 바실러스속 미생물을 이용한 대두피 또는 흑두피 발효방법,그리고 및 대두피 또는 흑두피 발효물을 함유하는 조성물 | |
CN111904878B (zh) | 一种含有玫瑰发酵液的脂质体的制备方法及应用 | |
Meshram et al. | Potential fibrinolytic activity of an endophytic Lasiodiplodia pseudotheobromae species | |
CN109288042A (zh) | 一种利用益生菌发酵海带制备恶性肿瘤医用食品原料的方法与应用 | |
CN116948901A (zh) | 食窦魏斯氏菌d-2胞外多糖在抑制结肠癌细胞中的应用 | |
JP2022531109A (ja) | 熱損傷の治療におけるロドコッカスルーバー製品の使用 | |
CN103463143A (zh) | 微藻肽皮肤抗菌止痒消炎消肿剂的制备方法及其应用 | |
JP2007159569A (ja) | ジオトリカム属菌を用いたキチン・キトサンを含む多糖体含有物の製造方法 | |
CN115252757A (zh) | 一种海洋生物物理屏障护创膜及其制备方法 | |
CN111630152A (zh) | 用于治疗皮肤损伤的细菌分泌物组 | |
CN114470007A (zh) | 含乳酸菌发酵产物之创伤外用组合物及其用途 | |
CN114231576A (zh) | 罗伊氏乳杆菌在制备植物多糖中的应用 | |
CN106754413B (zh) | 一种香椿内生真菌ts4及其次级代谢产物、制备方法和应用 | |
Gao et al. | ACE inhibitory, antitumor and antioxidant activities of submerged culture materials of three medicinal mushrooms | |
CN1213774C (zh) | 一种生物敷料的生产制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170922 |
|
RJ01 | Rejection of invention patent application after publication |